Refining Immunotherapy for the Treatment of Gastric Cancer with High Microsatellite Instability

Rishi Jain; Crystal S. Denlinger; Efrat Dotan

doi:10.1001/jamaoncol.2021.0091

Refining Immunotherapy for the Treatment of Gastric Cancer with High Microsatellite Instability

Rishi Jain
, Crystal S. Denlinger
, Efrat Dotan

Internal Medicine

Research output: Contribution to journal › Comment/debate

4 Scopus citations

Original language	English
Pages (from-to)	902-903
Number of pages	2
Journal	JAMA Oncology
Volume	7
Issue number	6
DOIs	https://doi.org/10.1001/jamaoncol.2021.0091
State	Published - Jun 2021

Access to Document

10.1001/jamaoncol.2021.0091

Cite this

@article{52ef992b34464ba39c640b3c1ed01906,

title = "Refining Immunotherapy for the Treatment of Gastric Cancer with High Microsatellite Instability",

author = "Rishi Jain and Denlinger, \{Crystal S.\} and Efrat Dotan",

note = "Funding Information: receiving grants from NGM Biopharmaceuticals outside the submitted work. Dr Denlinger reported receiving grants from Agios Pharmaceuticals, Amgen, Array BioPharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Exelixis, Genmab, MacroGenics, Merrimack Pharmaceuticals, and Zymeworks; personal fees from Astellas Pharma, Bayer, BeiGene, Bristol Myers Squibb, Eli Lilly, Exelixis, Merck, Taiho Oncology, and Zymeworks; and nonfinancial support from AstraZeneca outside the submitted work. Dr Dotan reported receiving grants from AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Incyte, MedImmune, Merck, OncoMed Pharmaceuticals, Pfizer, and Sumitomo Dainippon Pharma Oncology and personal fees from Armo BioSciences, Basilea Pharmaceutica, Pfizer, QED Therapeutics, and Sumitomo Dainippon Pharma Oncology outside the submitted work. No other disclosures were reported.",

year = "2021",

month = jun,

doi = "10.1001/jamaoncol.2021.0091",

language = "English",

volume = "7",

pages = "902--903",

journal = "JAMA Oncology",

issn = "2374-2437",

number = "6",

}

TY - JOUR

T1 - Refining Immunotherapy for the Treatment of Gastric Cancer with High Microsatellite Instability

AU - Jain, Rishi

AU - Denlinger, Crystal S.

AU - Dotan, Efrat

N1 - Funding Information: receiving grants from NGM Biopharmaceuticals outside the submitted work. Dr Denlinger reported receiving grants from Agios Pharmaceuticals, Amgen, Array BioPharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Exelixis, Genmab, MacroGenics, Merrimack Pharmaceuticals, and Zymeworks; personal fees from Astellas Pharma, Bayer, BeiGene, Bristol Myers Squibb, Eli Lilly, Exelixis, Merck, Taiho Oncology, and Zymeworks; and nonfinancial support from AstraZeneca outside the submitted work. Dr Dotan reported receiving grants from AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Incyte, MedImmune, Merck, OncoMed Pharmaceuticals, Pfizer, and Sumitomo Dainippon Pharma Oncology and personal fees from Armo BioSciences, Basilea Pharmaceutica, Pfizer, QED Therapeutics, and Sumitomo Dainippon Pharma Oncology outside the submitted work. No other disclosures were reported.

PY - 2021/6

Y1 - 2021/6

UR - https://www.scopus.com/pages/publications/85103548757

U2 - 10.1001/jamaoncol.2021.0091

DO - 10.1001/jamaoncol.2021.0091

M3 - Comment/debate

C2 - 33792611

AN - SCOPUS:85103548757

SN - 2374-2437

VL - 7

SP - 902

EP - 903

JO - JAMA Oncology

JF - JAMA Oncology

IS - 6

ER -

Refining Immunotherapy for the Treatment of Gastric Cancer with High Microsatellite Instability

Access to Document

Other files and links

Cite this